ROCKVILLE, Md., Feb. 5, 2013 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics
and innovative medicines for serious infections and diseases,
announced today that its Chief Executive Officer, Jeffrey Riley, will present at the 2013 BIO CEO
& Investor Conference. The conference will be held February 11-12, 2013 at the Waldorf-Astoria Hotel
in New York City. Mr. Riley is
scheduled to present on Tuesday, February
12, 2013 at 11:00 a.m. (Eastern
Time).
A live webcast of Synthetic Biologics' presentation can be
accessed by logging onto the web at
http://www.veracast.com/webcasts/bio/ceoinvestor2013/06212103.cfm.
After the presentation, a replay will be archived and accessible
for 30 days at the same website.
Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, and its EVP, Research &
Development, John Monahan, Ph.D.,
will be available to participate in one-on-one meetings with
investors who are registered to attend the conference.
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the
development of product candidates for serious infections and
diseases. Synthetic Biologics is developing a biologic for the
prevention of C. difficile infection, and a series of
monoclonal antibodies for the treatment of serious infectious
diseases, including pertussis and Acinetobacter. The Company
is also developing a synthetic DNA-based therapy for the treatment
of pulmonary arterial hypertension. In addition, the Company is
developing a drug candidate for the treatment of
relapsing-remitting multiple sclerosis (MS) and cognitive
dysfunction in MS, and is designing a clinical development pathway
for the treatment of amyotrophic lateral sclerosis. For more
information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
To download Synthetic Biologics' investor relations mobile
device app, which allows users access to the Company's SEC
documents, press releases and events, please click on the following
links to download the IRapp on your iPhone and iPad or your Android
mobile device.
SOURCE Synthetic Biologics, Inc.